OR WAIT 15 SECS
Stephanie Sutton was an assistant editor at Pharmaceutical Technology Europe.
The global API market has expanded from $69 billion in 2004 to more than $90 billion in 2008, according to a report from the Italian Chemical Pharmaceutical Association (CPA); in particular, the report noted a rapid growth rate for generic APIs.
The global active pharmaceutical ingredient (API) market has expanded from $69 billion in 2004 to more than $90 billion in 2008, according to a report from the Italian Chemical Pharmaceutical Association (CPA). In particular, the report noted a rapid growth rate for generic APIs.
According to the report, The World APIs Market, the market for generic APIs has grown from $12 billion in 2004 to $17 billion in 2008 at an average annual rate of 9.1%. However, the same cannot be said for branded/innovative APIs, which have grown at an average yearly rate of only 4.4% (from $16 billion in 2004 to $19 billion in 2008).
Unsurprisingly, the report attributes this trend to the same factors that are affecting other aspects of the pharmaceutical industry: the rising costs of discovering and launching new molecules into the market, and the increased uptake of generics, which are available for most of today's common illnesses and can be up to 90% cheaper than an innovator drug.
The market rulers
The majority of the 2008 global merchant API market (the API market that is produced externally by third-party manufacturers to pharmaceutical companies) was dominated by North America (44.7% market share, with the US accounting for 41.9%). However, the figures show a different story when it comes to the 2008 generic API market; Asia/Pacific led the way with a 34.8% market share while North America accounted for just under 25% of the global market. China has also become a strong player, accounting for 19.2% (compared with 15.1% in 2004) of the 2008 market, and is now the largest consumer of generic APIs in the world after the US.
According to the report, China, as well as India, registered the fastest growth rates in the world (more than 11.8% and more than 15.8%, respectively) and the two countries now account for approximately one quarter of the global merchant generic API market. Other developing countries have also experienced rapid annual growth rates in generic APIs, including Latin America (more than 9.4%, with growth mainly concentrated in Brazil) and Eastern Europe (more than 9.4%).
Meanwhile, countries in Western Europe haven't fared so well; particularly since the region's R&D-based pharma industry has been losing competitiveness to the US. The generic API market has been more dynamic than that for innovative APIs; however, growth rates have still been slow. Penetration of generic medicines in Western Europe is only 43% compared with 68% in the US, which the report attributes to differing regulatory frameworks between the two continents and a more consolidated mentality to generics in the US.
According to the report, the generic API market is expected to continue to grow at a faster rate than that for innovative APIs. During the next 5 years, the generic API merchant market is forecast to rise at an average annual rate of 11.4% from $17 billion in 2008 to $29.2 billion in 2013; the market for branded/innovative APIs will experience average yearly growth of only 1.8% to reach $20.8 billion in 2013. Overall, the global API merchant market is expected to reach $50 billion in 2013.
For generic APIs, the countries to watch will be Brazil, Russia, India and China, which are all expected to experience double-digit growth rates, according to the report. China will be the fastest growing market with an annual predicted growth rate of more than 18%; by 2013, the country's generic API merchant market is expected reach $7.6 billion.